Fol­low­ing bis­pe­cif­ic deal with Pfiz­er, qui­et Cal­i­for­nia biotech rais­es $65M, heads to the clin­ic

At the be­gin­ning of the year, Dren Bio penned a deal with Pfiz­er for a po­ten­tial $1 bil­lion for its bis­pe­cif­ic an­ti­body plat­form. The de­tails sur­round­ing the deal were sparse, and the de­tails on Dren Bio’s plat­form spars­er.

Fol­low­ing that deal, the pri­vate, San Car­los, CA-based biotech has raised $65 mil­lion in its sec­ond round of fi­nanc­ing, Dren Bio an­nounced Tues­day. The mon­ey will go to­wards two pro­grams: a first clin­i­cal tri­al this year for an an­ti­body treat­ment for large gran­u­lar lym­pho­cyt­ic leukemia or cy­to­tox­ic lym­phomas, and the bis­pe­cif­ic plat­form that was the cen­ter­piece of the Pfiz­er deal, ac­cord­ing to Dren Bio CEO Ne­nad Toma­se­vic in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER